These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 6998360)

  • 21. In vivo antitumor activity of 5-hydroxy-6-[N,N-bis(2-chloroethyl)aminomethyl]naphthalene-1,8- carbolactone.
    Riondel J; Boitard M; Bouaziz Z; Fillion H
    Pharmazie; 1992 Jan; 47(1):67-8. PubMed ID: 1608991
    [No Abstract]   [Full Text] [Related]  

  • 22. Anticancer potentiality of three new synthetic nitrogen mustards.
    Téllez-Martínez J; García-Cavazos R; Yáñez R; González-Diddi M
    Arch Invest Med (Mex); 1983; 14(2):159-71. PubMed ID: 6639257
    [No Abstract]   [Full Text] [Related]  

  • 23. The Ernst W. Bertner Memorial Award lecture: the evolution of biological heterogeneity in metastatic neoplasms.
    Fidler IJ
    Symp Fundam Cancer Res; 1983; 36():5-26. PubMed ID: 6382521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generation of lung cancer cell line variants by drug selection or cloning.
    Breen L; Keenan J; Clynes M
    Methods Mol Biol; 2011; 731():125-33. PubMed ID: 21516403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IP6-induced growth inhibition and differentiation of HT-29 human colon cancer cells: involvement of intracellular inositol phosphates.
    Yang GY; Shamsuddin AM
    Anticancer Res; 1995; 15(6B):2479-87. PubMed ID: 8669811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor.
    Heppner GH; Dexter DL; DeNucci T; Miller FR; Calabresi P
    Cancer Res; 1978 Nov; 38(11 Pt 1):3758-63. PubMed ID: 698935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneity in growth pattern and drug sensitivity of primary tumor and metastases in the human tumor colony-forming assay.
    Schlag P; Schreml W
    Cancer Res; 1982 Oct; 42(10):4086-9. PubMed ID: 7105006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of drug sensitivity among tumor cells within a tumor, between primary tumor and metastases, and between different metastases in the human tumor colony-forming assay.
    Tanigawa N; Mizuno Y; Hashimura T; Honda K; Satomura K; Hikasa Y; Niwa O; Sugahara T; Yoshida O; Kern DH
    Cancer Res; 1984 Jun; 44(6):2309-12. PubMed ID: 6202397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytotoxicity of estramustine, a steroid-nitrogen mustard derivative, through non-DNA targets.
    Tew KD; Erickson LC; White G; Wang AL; Schein PS; Hartley-Asp B
    Mol Pharmacol; 1983 Sep; 24(2):324-8. PubMed ID: 6888373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The primary in vitro antitumor screening of "half-mustard type" phenothiazines.
    Wuonola MA; Palfreyman MG; Motohashi N; Kawase M; Gabay S; Nacsa J; Molnár J
    Anticancer Res; 1997; 17(5A):3409-23. PubMed ID: 9413180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The primary in vitro anticancer activity of "half-mustard type" phenothiazines in NCI's revised anticancer screening paradigm.
    Wuonola MA; Palfreyman MG; Motohashi N; Kawase M; Gabay S; Gupta RR; Molnár J
    Anticancer Res; 1998; 18(1A):337-48. PubMed ID: 9568100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
    Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticancer chemosensitivity and growth rate of freshly separated human colorectal cancer cells assessed by in vitro DNA synthesis inhibition assay.
    Kawabata K; Nio Y; Imamura M; Fukumoto M
    Anticancer Res; 1998; 18(3A):1633-40. PubMed ID: 9673382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic implications of tumor heterogeneity.
    Heppner GH; Miller BE
    Semin Oncol; 1989 Apr; 16(2):91-105. PubMed ID: 2652316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implications of tumor cell heterogeneity for in vitro drug sensitivity testing.
    Von Hoff DD
    Semin Oncol; 1985 Sep; 12(3):327-31. PubMed ID: 4048966
    [No Abstract]   [Full Text] [Related]  

  • 36. Studies on the sensitivity of anticancer agents of normal human cells in culture.
    Morasca L; Balconi G; Erba E; Cvitkovic E
    Adv Exp Med Biol; 1975; 53():511-9. PubMed ID: 1121934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy sensitivity testing in human tumours.
    Richmond HG; Billington RW
    J Clin Pathol; 1981 Apr; 34(4):343-50. PubMed ID: 7240421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterogeneity of tumor cells.
    Ujházy V; Siracký J
    Antibiot Chemother (1971); 1980; 28():120-2. PubMed ID: 6998360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Results of in vitro chemosensitivity assays: human tumor clonogenic and scintillation assay].
    Tanigawa N; Morimoto H; Akita T; Inoue H; Tanaka T
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1176-84. PubMed ID: 3729439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.
    Poste G
    Cancer Treat Rep; 1986 Jan; 70(1):183-99. PubMed ID: 3510734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.